13F Pro Quality Score
Limited institutional coverage
Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 2 institutional filers currently hold this stock.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
Reported revenue, net income and operating margin by fiscal year, from Lakefront Biotherapeutics NV's annual filings on SEC EDGAR.
| Period | Form | Revenue | Net income | Op. marginOperating margin |
|---|---|---|---|---|
| FY 2025 | 20-F | $1.1B | $320.9M | 26.5% |
| FY 2024 | 20-F | $275.6M | $74.1M | -68.3% |
| FY 2023 | 20-F | $239.7M | $211.7M | -36.8% |
| FY 2022 | 20-F | $241.2M | $-218.0M | -54.3% |
| FY 2021 | 20-F | $234.4M | $-103.2M | -73.2% |
| FY 2020 | 20-F | $478.1M | $-305.4M | -37.4% |
Lakefront Biotherapeutics NV (LKFT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. LKFT is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 2 institutional filers currently hold this stock. Based on the latest XBRL financial filings (FY 2025), Lakefront Biotherapeutics NV reports quarterly revenue of $1.1B, net income of $320.9M, an operating margin of 26.5%. LKFT trades on the Nasdaq exchange and files with the SEC under CIK 1421876. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LKFT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Lakefront Biotherapeutics NV directly from SEC EDGAR.
Financials through the period ended SEC EDGAR: CIK 1421876 →